B. Riley Financial Increases Oncology Institute (NASDAQ:TOI) Price Target to $8.00

Oncology Institute (NASDAQ:TOI) had its target price lifted by equities researchers at B. Riley Financial from $6.00 to $8.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial’s price target indicates a potential upside of 181.69% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. BTIG Research reissued a “buy” rating and issued a $7.00 price objective on shares of Oncology Institute in a report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a report on Wednesday, January 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price target on shares of Oncology Institute in a research report on Monday, March 9th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Oncology Institute Stock Performance

TOI opened at $2.84 on Friday. The business’s 50-day simple moving average is $3.01 and its 200 day simple moving average is $3.39. Oncology Institute has a 52-week low of $0.63 and a 52-week high of $4.88. The firm has a market capitalization of $279.40 million, a PE ratio of -5.07 and a beta of 0.14.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $141.96 million during the quarter, compared to the consensus estimate of $139.78 million. Oncology Institute had a negative return on equity of 1,527.21% and a negative net margin of 11.45%.

Insider Transactions at Oncology Institute

In other Oncology Institute news, Director Brad Hively sold 13,333 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $3.77, for a total value of $50,265.41. Following the sale, the director owned 683,721 shares in the company, valued at $2,577,628.17. This represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Oncology Institute by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,545,245 shares of the company’s stock valued at $15,863,000 after acquiring an additional 264,358 shares during the period. Tiff Advisory Services LLC lifted its holdings in Oncology Institute by 22.0% during the 2nd quarter. Tiff Advisory Services LLC now owns 3,634,465 shares of the company’s stock valued at $7,451,000 after purchasing an additional 655,324 shares during the last quarter. CenterBook Partners LP boosted its position in Oncology Institute by 12.0% during the fourth quarter. CenterBook Partners LP now owns 3,029,312 shares of the company’s stock worth $10,784,000 after purchasing an additional 324,662 shares during the period. Kanen Wealth Management LLC increased its holdings in shares of Oncology Institute by 61.6% in the fourth quarter. Kanen Wealth Management LLC now owns 2,976,144 shares of the company’s stock valued at $10,712,000 after purchasing an additional 1,134,043 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its holdings in shares of Oncology Institute by 17.3% in the second quarter. Balyasny Asset Management L.P. now owns 2,518,337 shares of the company’s stock valued at $5,163,000 after purchasing an additional 371,005 shares during the last quarter. 36.86% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Oncology Institute

Here are the key news stories impacting Oncology Institute this week:

• Positive Sentiment: B. Riley raised its price target to $8.00 and put a Buy rating on TOI — the new target implies substantial upside versus recent levels, which can drive buying interest from investors and funds. Benzinga: B. Riley price target raise
• Positive Sentiment: Management reiterated FY‑2026 revenue guidance of $630M–$650M and said it is expanding delegated capitation partnerships — signals that growth and margin‑enhancing contract mix remain intact. MSN: TOI reiterates 2026 guidance
• Positive Sentiment: Q4 results showed record revenue and management highlighted the company’s first profitable quarter on the metrics discussed on the call (growth + improved profitability narrative), supporting the bullish sentiment. GlobeNewswire: Q4 and FY2025 results
• Neutral Sentiment: The company beat consensus for the quarter (revenue ~$142M vs. ~$139.8M est.; GAAP EPS better than expected at a loss of $0.06 vs. $0.08 est.), but details on EPS guidance were sparse in the release. Investors are parsing organic growth vs. one‑time items. MarketBeat: Q4 results & transcript
• Negative Sentiment: Despite the progress, the company still reports negative net margin and a large negative return on equity on reported GAAP metrics — execution risk remains on translating revenue growth into sustained GAAP profitability. MarketBeat: Financial metrics

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.